2 weeks Ago By ABMN Staff
Second Line Capital LLC boosted its holdings in shares of Merck & Co., Inc. ( NYSE:MRK – Free Report ) by 20.
0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,634 shares of the company’s stock after buying an additional 772 shares during the quarter. Second Line Capital LLC’s holdings in Merck & Co.
, Inc. were worth $577,000 as of its most recent SEC filing. Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business.
Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at $27,000.
Itau Unibanco Holding S.A. acquired a new stake in Merck & Co.
, Inc. in the second quarter valued at approximately $39,000. Abich Financial Wealth Management LLC raised its holdings in Merck & Co.
, Inc. by 121.8% in the second quarter.
Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after acquiring an additional 179 shares in the last quarter. Roble Belko & Company Inc grew its holdings in Merck & Co., Inc.
by 35.3% during the 1st quarter. Roble Belko & Company Inc now owns 326 shares of the company’s stock worth $43,000 after acquiring an additional 85 shares in the last quarter.
Finally, Strategic Financial Concepts LLC increased its stake in Merck & Co., Inc. by 1,475.
6% in the 2nd quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock valued at $43,000 after buying an additional 32,832 shares during the period. Hedge funds and other institutional investors own 76.
07% of the company’s stock. Merck & Co., Inc.
Price Performance Merck & Co., Inc. stock opened at $113.
69 on Monday. The firm has a market capitalization of $287.95 billion, a PE ratio of 126.
32, a P/E/G ratio of 1.60 and a beta of 0.39.
Merck & Co., Inc. has a 52 week low of $99.
14 and a 52 week high of $134.63. The firm’s 50-day simple moving average is $116.
70 and its 200 day simple moving average is $124.02. The company has a quick ratio of 1.
22, a current ratio of 1.47 and a debt-to-equity ratio of 0.80.
Merck & Co., Inc. Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Monday, October 7th.
Shareholders of record on Monday, September 16th will be given a dividend of $0.77 per share. This represents a $3.
08 annualized dividend and a yield of 2.71%. The ex-dividend date is Monday, September 16th.
Merck & Co., Inc.’s payout ratio is 342.
22%. Analyst Upgrades and Downgrades Several analysts have recently commented on MRK shares. Wells Fargo & Company reduced their target price on shares of Merck & Co.
, Inc. from $140.00 to $125.
00 and set an “equal weight” rating for the company in a research note on Wednesday, July 31st. Evercore ISI raised Merck & Co., Inc.
to a “strong-buy” rating in a report on Tuesday, July 30th. Barclays dropped their target price on Merck & Co., Inc.
from $145.00 to $142.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st.
Argus raised Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th.
Finally, Morgan Stanley upped their price objective on Merck & Co., Inc. from $132.
00 to $134.00 and gave the stock an “equal weight” rating in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and four have assigned a strong buy rating to the stock.
Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $134.58. View Our Latest Report on MRK Merck & Co.
, Inc. Company Profile ( Free Report ) Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health.
The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. Further Reading Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co.
, Inc. ( NYSE:MRK – Free Report ). Receive News & Ratings for Merck & Co.
Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc.
and related companies with MarketBeat.com's FREE daily email newsletter ..
